Across TCGA pan-cancer cohorts, OR9I2P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated OR9I2P data layer.
The strongest signal is observed in mesothelioma (MESO), where higher OR9I2P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR9I2P expression acts as an unfavorable survival marker, although some lineages such as STAD and CESC show a favorable association.
MESO, BRCA, and STAD are the cancer types where OR9I2P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.